Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herentals – page 12

2 092 clinical trials in Herentals, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herentals at a glance
2 092
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 092 trials in Herentals

Open in trial search

Phase 2 Randomized Trial of Oral NS-863 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ARGX-121
  • Sponsor:Argenx

Study of ZL-1310, BI 764532 and atezolizumab in patients with advanced small cell lung cancer and neuroendocrine tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Long‑Term Safety and Efficacy Study of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

Influenza+1

Recruiting

Study of the safety and immune response of gskvx000000077430 drug combination versus standard influenza vaccine in adults 18‑64 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Study of subcutaneous anifrolumab pharmacokinetics, pharmacodynamics and safety in children aged 5 to <18 years with systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herentals

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on follicular lymphoma and diffuse large B-cell lymphoma, evaluating novel therapeutic approaches against traditional treatments.

  • Comparative treatment studies
  • Safety and efficacy evaluation
  • Advanced lymphoma therapies

These trials aim to improve treatment outcomes for patients with various forms of lymphoma through targeted therapies.

02 Multiple Myeloma Research

Groundbreaking studies exploring early intervention in monoclonal gammopathy and smoldering multiple myeloma conditions.

  • Plasma cell disorders
  • Early disease intervention
  • Novel therapeutic approaches

Research focused on preventing progression to active multiple myeloma through innovative treatments.

03 Rheumatology Studies

Investigation of treatment strategies for rheumatoid arthritis, comparing conventional approaches with accelerated biological therapy access.

  • Early RA intervention
  • Long-term effectiveness
  • Treatment optimization

Comprehensive evaluation of various treatment approaches for better disease management outcomes.

04 Gastroenterology Research

Studies examining optimal approaches for PPI deprescription in patients with various gastrointestinal conditions including functional dyspepsia and reflux.

  • Medication optimization
  • Alternative treatment strategies
  • Patient-centered approaches

Focused on developing effective strategies for reducing long-term PPI use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.